• 

  Artificial Intelligence and Machine Learning in Drug Discovery (Part I)

  In a recent webinar, we surveyed our audience and were surprised to see that a significant majority of attendees thought the application of artificial intelligence and machine learning (AI/ML) methods was the most exciting area for drug discovery, beyond even degraders or molecular glues. Machine learning methods have been increasingly appearing in our Molecules of…

• 

  2021 Drug Discovery Biotech Mergers and Acquisitions Review

  We reviewed all of the biotech mergers and acquisitions in 2021 and did a deep dive on the list of biotech M&A transactions focused on drug discovery. In this series, we provide a high level overview of: The drug discovery biotech acquisitions by total consideration in 2021 The lead molecules in each acquisition and their…

• 

  First Disclosures of Small Molecule Drug Candidates – EFMC-ISMC 2021

  By Christian Kuttruff and Julien Lefranc The first disclosures of new drug candidates are always the highlight of medicinal chemistry conferences. Six novel drug candidates were recently disclosed by European companies at the European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (EFMC-ISMC) Conference in Basel, including a KRAS G12C inhibitor from Novartis, an…

• 

  Scientific Highlights from 2020’s Drug Discovery Biotech IPOs

  Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured reviewers from our community what stood out to them about the science of this group of companies, and here are some highlights that emerged from the discussion. Any thoughts and comments shared are personal opinions only and…

• 

  2020 Biotech IPOs – Small Molecule R&D Companies

  Looking at the pipelines of recent biotech IPOs is a great way to get a snapshot of new technologies and approaches to drug discovery or to see what’s coming in smaller indications. Complementing our recent highlight of large molecule-focused companies, below is a summary of 2020’s class of biotech IPOs focused on small molecule drug…

• 

  2020 Biotech IPOs – Large Molecule R&D Companies

  Browsing through the pipelines of recent biotech IPOs is great way to catch up on emerging targets, novel drug modalities, and science at the edge of development. Unlike conferences and publications which tend to be a lagging indicator of what’s going on in industry (with many publications only being released years after a program has…